Moderna and BioNTech, two rising stars in biotech, were in the limelight this year with their pioneering mRNA vaccines against COVID-19. Just who are these companies and who is behind them ...

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines ...

GSK says it owns seven patents that “provide the foundation” for Moderna’s messenger RNA vaccine portfolio, and is now suing the biotechnology company for infringement. At issue is the work ...

Think Tank Transcripts:Who Owns History? MR. WATTENBERG ... I think what revisionists, ifyou want to call them that, are pointing out is that the historicaldevelopment set in motion or symbolized ...

Just ask Brad Miller, Chief Information Officer (CIO) of Moderna. Brad is passionate about ... Our job is to help them be educated on the use of AI, including examples of use cases that we see ...

Vanguard Group Inc. raised its holdings in Moderna by 15.1% in the first quarter. Vanguard Group Inc. now owns 39,036,872 shares of the company’s stock worth $4,159,769,000 after purchasing an ...

Moderna's Q3 Earnings Beat Overshadowed By Vaccine Demand Slowdown And Market Share Concerns, Analysts Warn Moderna's stock faces a decline as analysts lower the price target to $90, citing weaker ...

Among the contributors, about 71% of them worked for the federal ... of Allergy and Infectious Diseases (NIAID) owns half of the patent for the Moderna COVID-19 vaccine, among thousands of other ...

Know other book lovers who might like this guide? Forward them this email. When you buy a book using a link in this newsletter, we receive a commission. Thank you for supporting The Atlantic.

18 analysts have expressed a variety of opinions on Moderna (NASDAQ ... the changing sentiments over the past 30 days and comparing them to the preceding months. The 12-month price targets ...

It's been a sad week for Moderna, Inc. ( NASDAQ:MRNA ), who've watched their investment drop 14% to US$46.83 in the... On Thursday, Moderna Inc. (NASDAQ:MRNA) reported third-quarter revenue of $1. ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...